Document is current
Any future updates will be listed below
-
Authors
Aguilar-Pérez, Clara https://orcid.org/0000-0001-7438-9141
Lenaerts, Anne J.
Villellas, Cristina
Guillemont, Jerome
Dallow, John
Painter, Hannah
Ammerman, Nicole C.
Hassan, Anis
Golovkine, Guillaume https://orcid.org/0000-0001-8388-5892
Brock, Laure
Sordello, Sylvie
Chauffour, Aurélie https://orcid.org/0000-0002-8846-5069
Aubry, Alexandra
Mai, Thi Cuc
Wong, Sarah
Clark, Taane G. https://orcid.org/0000-0001-8985-9265
Nam, Kiyean
Kim, Jeongjun
Choi, Jinho
Crabbe, Marjolein
Esquivias, Jorge
Lounis, Nacer
Stoops, Bart
Amssoms, Katie
Bartolome-Nebreda, Jose M.
Gruppo, Veronica
Robertson, Gregory T. https://orcid.org/0000-0001-7157-4034
Veziris, Nicolas
Upton, Anna M.
Nuermberger, Eric L. https://orcid.org/0000-0003-1440-9889
Cox, Vivian
Ballell, Lluis
Baeten, Benny
Koul, Anil https://orcid.org/0009-0009-5542-4568
Pym, Alexander S.
Wall, Richard J. https://orcid.org/0000-0003-3487-3187
Lamprecht, Dirk A. https://orcid.org/0000-0003-1066-9026
- License Information
-
More Information
Article History
Received: 4 November 2024
Accepted: 12 September 2025
First Online: 22 October 2025
Competing interests
: J.G., C.V. and D.A.L. have been named inventors in a patent application for JNJ-2901 and JNJ-4052 compounds. C.A.-P., C.V., J.G., M.C., J.E., N.L., B.S., J.M.B.-N., V.C., LBallell, B.B., A.K., A.S.P. and D.A.L. were/are all full-time employees of Janssen, a Johnson & Johnson company, and/or potential stockholders of Johnson & Johnson. G.G., LBrock, S.S. and A.U. were/are all full-time employees of Evotec. K.N., J.K. and J.C. were/are full-time employees of Qurient Co. Ltd. J.D., H.P., A.H., A.K., A.J.L., G.T.R., N.C.A., V.G., E.L.N. and R.J.W. received funding from Janssen Pharmaceutica to perform contract research. The other authors declare no competing interests.
